<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fludarabine is becoming the initial therapy for low-grade lymphoproliferative <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, such as CLL and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity </plain></SENT>
<SENT sid="2" pm="."><plain>Progressive multifocal <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> (PML) is an <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with JC virus of the white matter of the central <z:mp ids='MP_0008912'>nervous</z:mp> system seen mostly in immunosuppressed patients </plain></SENT>
<SENT sid="3" pm="."><plain>We describe two patients treated with fludarabine who developed PML </plain></SENT>
<SENT sid="4" pm="."><plain>Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them </plain></SENT>
<SENT sid="5" pm="."><plain>We suggest that fludarabine may increase the risk of PML in patients with <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> </plain></SENT>
</text></document>